Monashee Investment Management LLC acquired a new stake in shares of Prevail Therapeutics Inc. (NASDAQ:PRVL) in the 2nd quarter, HoldingsChannel reports. The fund acquired 90,000 shares of the company’s stock, valued at approximately $1,188,000.
Separately, SG Americas Securities LLC acquired a new position in Prevail Therapeutics during the 2nd quarter worth about $194,000. Institutional investors and hedge funds own 8.19% of the company’s stock.
Several research analysts have commented on the company. Morgan Stanley assumed coverage on Prevail Therapeutics in a report on Monday, July 15th. They set an “overweight” rating and a $20.00 target price on the stock. Cowen assumed coverage on Prevail Therapeutics in a report on Monday, July 15th. They set an “outperform” rating on the stock. Wedbush reaffirmed an “outperform” rating and set a $20.00 target price (down from $25.00) on shares of Prevail Therapeutics in a report on Thursday, August 15th. Finally, Bank of America assumed coverage on Prevail Therapeutics in a report on Monday, July 15th. They set a “buy” rating and a $15.00 target price on the stock.
Prevail Therapeutics (NASDAQ:PRVL) last announced its quarterly earnings data on Wednesday, August 14th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.24) by $0.66. Research analysts predict that Prevail Therapeutics Inc. will post -2.53 EPS for the current fiscal year.
In other Prevail Therapeutics news, Director Carl L. Gordon acquired 882,352 shares of the company’s stock in a transaction dated Monday, June 24th. The shares were bought at an average cost of $17.00 per share, with a total value of $14,999,984.00. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
Prevail Therapeutics Company Profile
Prevail Therapeutics Inc, a gene therapy company, focuses on developing and commercializing disease-modifying AAV-based gene therapies for patients with devastating neurodegenerative diseases. The company's lead product candidate is PR001 for the treatment of Parkinson's disease with GBA1 mutation and neuronopathic Gaucher disease.
Further Reading: What is the cash asset ratio?
Want to see what other hedge funds are holding PRVL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Prevail Therapeutics Inc. (NASDAQ:PRVL).
Receive News & Ratings for Prevail Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prevail Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.